Co-Diagnostics (NASDAQ:CODX) and SurModics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Institutional and Insider Ownership
10.6% of Co-Diagnostics shares are held by institutional investors. Comparatively, 86.7% of SurModics shares are held by institutional investors. 7.7% of SurModics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Co-Diagnostics and SurModics, as reported by MarketBeat.
||Strong Buy Ratings
Co-Diagnostics currently has a consensus target price of $2.00, indicating a potential upside of 73.91%. SurModics has a consensus target price of $68.00, indicating a potential upside of 70.43%. Given Co-Diagnostics’ higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than SurModics.
Earnings and Valuation
This table compares Co-Diagnostics and SurModics’ gross revenue, earnings per share and valuation.
||Earnings Per Share
SurModics has higher revenue and earnings than Co-Diagnostics.
This table compares Co-Diagnostics and SurModics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
SurModics beats Co-Diagnostics on 8 of the 10 factors compared between the two stocks.
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.